Personalized Medicine in Gynecological Oncology: Update and Challenge

A Special Issue of Journal of Personalized Medicine (ISSN 2075-4426) belonging to the section "Personalized Therapy in Clinical Medicine".

Deadline for manuscript submissions: 30 June 2027 | Viewed by 1805

Editor


E-Mail Website
Guest Editor
Department of Gynecology, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal
Interests: gynecologic oncology; ovarian tumor; gynecologic ultrasound; gynecology

Special Issue Information

Dear Colleagues,

Gynecological oncology has entered an era of precision medicine, where advances in molecular biology, imaging, and targeted therapies are reshaping how we diagnose and treat women with cancer. The integration of genomics, artificial intelligence, and advanced imaging techniques allows for increasingly individualised care, improving both oncological outcomes and quality of life.

This Special Issue of the Journal of Personalized Medicine, dedicated to Gynecological Oncology, aims to bring together contributions that reflect the current progress and future directions of the field. Topics of interest include innovations in surgical and non-surgical management, imaging-based prediction models, molecular profiling, biomarkers for treatment response, and the role of minimally invasive and fertility-preserving approaches.

By bridging translational research and clinical practice, this Special Issue seeks to emphasise the importance of personalised strategies that move beyond a “one-size-fits-all” paradigm, ensuring that every patient benefits from the most precise, effective, and compassionate care possible.

Dr. Patrícia Pinto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecologic oncology
  • personalized medicine
  • imaging and biomarkers
  • fertility-sparing surgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

13 pages, 2282 KB  
Systematic Review
Primary Clitoral Melanoma: Personalized Therapeutic Strategies Informed by Clinical Evidence and Systematic Review
by Anna Pitsillidi, Laura Vona, Guglielmo Stabile and Günter Noé
J. Pers. Med. 2026, 16(2), 70; https://doi.org/10.3390/jpm16020070 - 31 Jan 2026
Cited by 2 | Viewed by 1037
Abstract
Introduction: Mucosal melanomas are rare, and vulvar melanoma is typically diagnosed at an advanced stage with aggressive behavior and poor prognosis. The clitoral region adds challenges due to its functional importance and lack of a dedicated staging system, requiring individualized management. This review [...] Read more.
Introduction: Mucosal melanomas are rare, and vulvar melanoma is typically diagnosed at an advanced stage with aggressive behavior and poor prognosis. The clitoral region adds challenges due to its functional importance and lack of a dedicated staging system, requiring individualized management. This review evaluates current evidence on prognosis with emphasis on clitoral involvement and highlights diagnostic and therapeutic challenges, underscoring the need for personalized strategies and prospective multicentre studies. Materials and Methods: A systematic review, registered in PROSPERO (CRD420251151187), was conducted per PRISMA guidelines across PubMed, Scopus, Embase, and Web of Science, including English-language case reports and series of primary clitoral melanoma published until August 2025, with no historical limits. Results: 15 cases from 10 studies were identified. The mean patient age was 60 years, with most tumors presenting at advanced stages (median Breslow thickness of 8 mm, frequent ulceration). Immunohistochemical markers and gene mutations are rarely investigated in reported cases. All patients underwent surgery, with variable lymph node assessment; adjuvant therapy was rarely used. Recurrence occurred in nearly one-third of cases, sometimes more than 10 years after initial treatment. Conclusions: Primary clitoral melanoma is extremely rare and often diagnosed late, underscoring the need for heightened clinical awareness. Wide local excision with organ preservation is preferred, and bilateral sentinel lymph-node biopsy can improve staging. The absence of a dedicated staging system and limited systemic evidence highlight the need for standardized protocols. Emerging molecular and immunologic approaches are promising, but prospective multicentre studies are essential to guide management. Full article
(This article belongs to the Special Issue Personalized Medicine in Gynecological Oncology: Update and Challenge)
Show Figures

Figure 1

Back to TopTop